Get startedLog in
    Picture of BioMarin Pharmaceutical logo

    BMRN — BioMarin Pharmaceutical News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapNeutral
    All News

    Brief: BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN®

    Picture of BioMarin Pharmaceutical logoBioMarin Pharmaceutical
    24/06/2025 14:04
    June 24 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:

BIOMARIN PRESENTS FIVE-YEAR PHASE 3 RESULTS REINFORCING LONG-TERM EFFICACY AND SAFETY OF ROCTAVIAN® (VALOCTOCOGENE ROXAPARVOVEC-RVOX) AT INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS 2025 CONGRESS

BIOMARIN PHARMACEUTICAL INC - NO NEW SAFETY SIGNALS OBSERVED IN 5-YEAR ROCTAVIAN STUDY

Source text: ID:nPn9r74zka

Further company coverage: BMRN.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on BioMarin Pharmaceutical

    See all news